Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Alto Neuroscience, Inc.ANRO · Entity 4755 | Director | March 08, 2024 | March 12, 2024 |
| Candel Therapeutics, Inc.CADL · Entity 4969 | Director | June 23, 2026 | June 24, 2026 |
| Entrada Therapeutics, Inc.TRDA · Entity 2163 | Director | June 10, 2026 | June 12, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Alto Neuroscience, Inc.
Report date March 08, 2024 · Filed March 12, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $13.76 · Expires 2034-03-07 | Direct | 30,574 |
Reported balance
After 2024-03-08 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2024-03-08 · Grant · Acquired 30,574 · Balance 30,574 F1: The shares underlying the option shall vest in 36 equal monthly installments commencing on April 8, 2024, subject to the Reporting Person's continuous service through each vesting date. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $13.76 · Expires 2034-03-07 | Direct | 1,590 |
Reported balance
After 2024-03-08 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2024-03-08 · Grant · Acquired 1,590 · Balance 1,590 F3: This option was issued to the Reporting Person pursuant to the Issuer's Non-Employee Director Compensation Policy in lieu of retainer fees of $16,263.74. F2: 123 shares underlying the option shall vest on March 31, 2024, and 489 shares underlying the option shall vest on each of June 30, 2024, September 30, 2024 and December 31, 2024, subject to the Reporting Person's continuous service through each such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares underlying the option shall vest in 36 equal monthly installments commencing on April 8, 2024, subject to the Reporting Person's continuous service through each vesting date.
F2: 123 shares underlying the option shall vest on March 31, 2024, and 489 shares underlying the option shall vest on each of June 30, 2024, September 30, 2024 and December 31, 2024, subject to the Reporting Person's continuous service through each such vesting date.
F3: This option was issued to the Reporting Person pursuant to the Issuer's Non-Employee Director Compensation Policy in lieu of retainer fees of $16,263.74.
Candel Therapeutics, Inc.
Report date June 23, 2026 · Filed June 24, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.08 · Expires 2036-06-23 | Direct | 32,000 |
Reported balance
After 2026-06-23 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-23 · Grant · Acquired 32,000 · Balance 32,000 F1: This option is subject to time-based vesting. The shares underlying this option shall vest and become exercisable upon the earlier of (i) June 23, 2027 or (ii) the date of the next Annual Meeting of Stockholders of the Issuer; provided, however, that all vesting shall cease if the Reporting Person resigns from the Board of Directors (the "Board") of the Issuer or otherwise ceases to serve as a director, unless the Board determines that the circumstances warrant continuation of vesting. |
Filing footnotes · ownership attribution and instrument terms
F1: This option is subject to time-based vesting. The shares underlying this option shall vest and become exercisable upon the earlier of (i) June 23, 2027 or (ii) the date of the next Annual Meeting of Stockholders of the Issuer; provided, however, that all vesting shall cease if the Reporting Person resigns from the Board of Directors (the "Board") of the Issuer or otherwise ceases to serve as a director, unless the Board determines that the circumstances warrant continuation of vesting.
Entrada Therapeutics, Inc.
Report date June 10, 2026 · Filed June 12, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.97 · Expires 2036-06-10 | Direct | 19,000 |
Reported balance
After 2026-06-10 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-10 · Grant · Acquired 19,000 · Balance 19,000 F1: The shares subject to this option shall vest and become exercisable on the earlier of (i) the one-year anniversary of June 10, 2026 or (ii) the Issuer's next annual meeting of stockholders. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares subject to this option shall vest and become exercisable on the earlier of (i) the one-year anniversary of June 10, 2026 or (ii) the Issuer's next annual meeting of stockholders.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 23, 2026 Filed Jun 24, 2026 20:36 UTC | Candel Therapeutics, Inc. CADL · Entity 4969 | GrantStock Option (Right to Buy) · Derivative | 32,000 | $0.00 Strike: $9.08 | $0.00 |
DisclosureSEC source: 0002013423-26-000004 · ownership.xml · derivative · entry 1 Radhakrishnan Maha · CIK 0002013423 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 32,000 Underlying: Common Stock · 32,000 shares Expires 2036-06-23 F1 · derivative.exercise_date: This option is subject to time-based vesting. The shares underlying this option shall vest and become exercisable upon the earlier of (i) June 23, 2027 or (ii) the date of the next Annual Meeting of Stockholders of the Issuer; provided, however, that all vesting shall cease if the Reporting Person resigns from the Board of Directors (the "Board") of the Issuer or otherwise ceases to serve as a director, unless the Board determines that the circumstances warrant continuation of vesting. Read SEC document |
| June 10, 2026 Filed Jun 12, 2026 21:05 UTC | Entrada Therapeutics, Inc. TRDA · Entity 2163 | GrantStock Option (Right to Buy) · Derivative | 19,000 | $0.00 Strike: $5.97 | $0.00 |
DisclosureSEC source: 0002013423-26-000002 · wk-form4_1781298346.xml · derivative · entry 1 Radhakrishnan Maha · CIK 0002013423 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,000 Underlying: Common Stock · 19,000 shares Expires 2036-06-10 F1 · derivative.exercise_date: The shares subject to this option shall vest and become exercisable on the earlier of (i) the one-year anniversary of June 10, 2026 or (ii) the Issuer's next annual meeting of stockholders. Read SEC document |
| June 04, 2025 Filed Jun 6, 2025 20:36 UTC | Candel Therapeutics, Inc. CADL · Entity 4969 | GrantStock Option (Right to Buy) · Derivative | 28,480 | $0.00 Strike: $5.60 | $0.00 |
DisclosureSEC source: 0000950170-25-083163 · ownership.xml · derivative · entry 1 Radhakrishnan Maha · CIK 0002013423 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,480 Underlying: Common Stock · 28,480 shares Expires 2035-06-04 F1 · derivative.exercise_date: The shares underlying this option shall vest and become exercisable in 36 equal monthly installments, subject to the Reporting Person's continued service on each such vesting date. Read SEC document |
| June 01, 2025 Filed Jun 3, 2025 12:13 UTC | Entrada Therapeutics, Inc. TRDA · Entity 2163 | GrantStock Option (Right to Buy) · Derivative | 38,000 | $0.00 Strike: $7.60 | $0.00 |
DisclosureSEC source: 0001689375-25-000029 · wk-form4_1748952778.xml · derivative · entry 1 Radhakrishnan Maha · CIK 0002013423 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 38,000 Underlying: Common Stock · 38,000 shares Expires 2035-06-01 F1 · derivative.exercise_date: The stock option shall vest in equal monthly installments over three years from the date of grant, subject to the reporting person's continuous service through the applicable vesting date. Read SEC document |
| March 08, 2024 Filed Mar 12, 2024 20:49 UTC | Alto Neuroscience, Inc. ANRO · Entity 4755 | GrantStock Option (right to buy) · Derivative | 1,590 | $10.21 Strike: $13.76 | $16,238.67 |
DisclosureSEC source: 0001415889-24-007643 · form4-03122024_080330.xml · derivative · entry 2 Radhakrishnan Maha · CIK 0002013423 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,590 Underlying: Common Stock · 1,590 shares Expires 2034-03-07 F3 · price: This option was issued to the Reporting Person pursuant to the Issuer's Non-Employee Director Compensation Policy in lieu of retainer fees of $16,263.74. F2 · derivative.exercise_date: 123 shares underlying the option shall vest on March 31, 2024, and 489 shares underlying the option shall vest on each of June 30, 2024, September 30, 2024 and December 31, 2024, subject to the Reporting Person's continuous service through each such vesting date. Read SEC document |
| March 08, 2024 Filed Mar 12, 2024 20:49 UTC | Alto Neuroscience, Inc. ANRO · Entity 4755 | GrantStock Option (right to buy) · Derivative | 30,574 | $0.00 Strike: $13.76 | $0.00 |
DisclosureSEC source: 0001415889-24-007643 · form4-03122024_080330.xml · derivative · entry 1 Radhakrishnan Maha · CIK 0002013423 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,574 Underlying: Common Stock · 30,574 shares Expires 2034-03-07 F1 · derivative.exercise_date: The shares underlying the option shall vest in 36 equal monthly installments commencing on April 8, 2024, subject to the Reporting Person's continuous service through each vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.